OmniAb, Inc. (OABI) NASDAQ
1.56
+0.06(+4.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.56
+0.06(+4.00%)
Currency In USD
Address
5980 Horton Street
EmeryVille, CA 94608
United States of America (the)
Phone
510 250 7800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
114
First IPO Date
September 30, 2021
| Name | Title | Pay | Year Born |
| Matthew W. Foehr | President, Chief Executive Officer & Director | 969,332 | 1973 |
| Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer | 677,485 | 1968 |
| Charles S. Berkman | Chief Legal Officer & Secretary | 695,487 | 1969 |
| Bill Harriman | Senior Vice President of Antibody Discovery | 0 | N/A |
| Christel Iffland | Senior Vice President of Antibody Technologies | 0 | N/A |
| Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research | 0 | N/A |
| Cia McCaffrey | Vice President of People & Talent | 0 | N/A |
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.